Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of all of outstanding shares of Mirati Therapeutics in a $5.8bn deal. The company plans to buy Mirati for $58 for each share in cash, representing an equity…

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of radiopharmaceutical company POINT Biopharma for an all-in cash price of $1.4bn. Lilly offered $12.5 for each share of POINT. POINT’s pipeline comprises radioligand…